A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Metastatic Breast Cancer

In brief

The Objectives of this study: The primary objective of the study was to evaluate progression-free survival (PFS) (defined as the number of days between the date of randomization and the date of clinical disease progression (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1, as assessed by Independent Radiology Review, or death for any cause, whichever occured first) in patients with metastatic triple-negative breast cancer (TNBC) treated with the combination of paclitaxel and orally administered reparixin compared to paclitaxel alone. The secondary objectives were: * To determine overall survival (OS). * To evaluate objective response rates (ORR). * To determine median PFS (mPFS). * To assess the safety of the combination of paclitaxel and orally administered reparixin (referred to as combination treatment).

Key facts

Study ID

NCT02370238

Run by

Dompé Farmaceutici S.p.A

People needed

194

Starts

2015-07-29

Expected to finish

2020-03-23

Last updated by the study team

2022-09-16

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female aged ≥ 18 years.
• Patients with pathologically documented metastatic triple negative breast cancer (TNBC), eligible for treatment with paclitaxel. Paraffin-embedded tissue must be available from metastatic sites, if reasonably accessible, or from the primary tumor, to confirm the diagnosis of TNBC and for correlative studies (only on metastatic tissue). Fifteen slides can be obtained if the full block is not available to be sent or released.
• TNBC will be defined as breast cancer with <1% ER+ and <1% PgR+ cells, and HER2 immunohistochemistry score of 0 or 1+ and/or in situ hybridization (ISH) with HER2 gene copy number <4 or a ratio of less than 2 between HER2 gene copy number and centromere of chromosome 17. Patients whose metastatic disease is TNBC are eligible even when their primary tumor expressed hormone receptors and/or HER2.
• Patients must be newly diagnosed metastatic or must have relapsed following a prior (neo)adjuvant chemotherapy regimen. If a taxane (i.e., paclitaxel or docetaxel) was administered as part of the (neo)adjuvant regimen, PD must have occurred > 12 months from the end of previous (neo)adjuvant treatment. For non-taxane (neo)adjuvant regimen, PD must have occurred > 6 months from the end of previous (neo)adjuvant treatment
• Patients with at least one baseline measurable lesion according to RECIST criteria version 1.1.
• Zubrod (Eastern Co-operative Oncology Group [ECOG]) Performance Status (PS) of 0-1.
• Life expectancy of at least three months.
• Patients must be able to swallow and retain oral medication (intact tablet).
• Able to undergo all screening assessments outlined in the protocol.
• Adequate organ function (defined by the following parameters):
• Serum creatinine < 140 μmol/L (< 1.6 mg/dL) or creatinine clearance > 60 mL/min.
• Serum hemoglobin ≥ 9 g/dL; absolute neutrophil count ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L.
• Serum bilirubin ≤ 1.5 x upper normal limit (UNL) except patients with Gilbert's syndrome
• Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 x UNL but ≤ 5.0 x UNL in case of liver metastases; alkaline phosphatase (ALP) ≤ UNL but i) ≤ 2.5 x UNL in case of liver metastases and ii) ≤ 5 UNL in case of bone metastases; albumin ≥ 2.5 g/dl.
• No history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease.
• No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus-I and -II positive status.
• Dated and signed IEC/IRB-approved informed consent.

You may not qualify if…

• Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological therapy), Patients may receive bisphosphonates and other therapies to treat bone metastases, however if used, bone lesions will not be considered as measurable disease.
• Less than four weeks since last radiotherapy (excluding palliative radiotherapy).
• Pregnancy or lactation or unwillingness to use adequate method of birth control.
• Neurological or psychiatric disorders which may influence understanding of study and informed consent procedures.
• Active or uncontrolled infection.
• Malabsorption syndrome, disease significantly affecting gastrointestinal function.
• G>1 pre-existing peripheral neuropathy
• Any other invasive malignancy from which the patient has been disease-free for less than 5 years with the exception of curatively treated basal or squamous cell skin cancer
• Hypersensitivity to:
• paclitaxel
• ibuprofen or to more than one non-steroidal anti-inflammatory drug.
• medications belonging to the class of sulfonamides, with the exception of sulfanilamides (e.g., sulfamethoxazole).

Where it is running

• CBCC Global Research a Comprehensive Blood and Cancer Center — Bakersfield, California, United States
• Florida Cancer Specialists — Daytona Beach, Florida, United States
• Florida Cancer Specialists — West Palm Beach, Florida, United States
• Atlanta Cancer Care — Alpharetta, Georgia, United States
• Northside Hospital, Inc.-Georgia Cancer Specialists — Athens, Georgia, United States
• Atlanta Cancer Care — Atlanta, Georgia, United States
• Northside Hospital, Inc. — Atlanta, Georgia, United States
• Northside Hospital, Inc.-Georgia Cancer Specialists — Canton, Georgia, United States
• Atlanta Cancer Care — Conyers, Georgia, United States
• Atlanta Cancer Care — Cumming, Georgia, United States
• Atlanta Cancer Care — Decatur, Georgia, United States
• Northside Hospital, Inc.-Georgia Cancer Specialists — Decatur, Georgia, United States
• Atlanta Cancer Care — Jonesboro, Georgia, United States
• Northside Hospital, Inc.-Georgia Cancer Specialists — Macon, Georgia, United States
• Northside Hospital, Inc.-Georgia Cancer Specialists — Marietta, Georgia, United States
• Southeastern Regional Medical Center — Newnan, Georgia, United States
• Northside Hospital, Inc.-Georgia Cancer Specialists — Sandy Springs, Georgia, United States
• Swedish Covenant — Chicago, Illinois, United States
• Mid Illinois Hematology & Oncology Associates, Ltd. — Normal, Illinois, United States
• University of Michigan Cancer Center — Ann Arbor, Michigan, United States
• Summit Medical Group — Morristown, New Jersey, United States
• Regional Cancer Care Associates — Sparta, New Jersey, United States
• Waverly Hematology Oncology — Cary, North Carolina, United States
• Hematology and Oncology Associates of Northeast PA — Dunmore, Pennsylvania, United States
• Southern Cancer Center — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.